Octagon Capital Advisors LP
Registered adviserRegulatory profile
From Form ADV, the SEC filer profile, 13D/13G type codes and N-CEN, never from the name.
| Rosters | Regulatory AUM | Main clients |
|---|---|---|
| Apr 2026 to Oct 2026 | $1,175,272,000 | Pooled investment vehicles (100%) |
| Apr 2025 to Mar 2026 | $919,787,000 | Pooled investment vehicles (100%) |
| Apr 2024 to Mar 2025 | $951,771,000 | Pooled investment vehicles (100%) |
| May 2023 to Mar 2024 | $1,074,417,782 | Pooled investment vehicles (100%) |
| Apr 2023 | $1,074,417,782 | Pooled investment vehicles (100%) |
| Apr 2022 to Mar 2023 | $1,116,417,000 | Pooled investment vehicles (100%) |
Portfolio style
Measured from the filed 13F common-share book for Jun 30, 2026, never from the firm's own description.
Closest benchmark: the Russell 2000 as of 2026-06-30, active share 98.5%; sector active share 90.9% against the combined 13F book's sector weights.
Over time 23 measured quarters
How the bands are measured
Style bands measure the filed 13F common-share book each closed quarter, tested in this order. Unknown: under $10,000,000 of valued equity or 5 stocks. Index-like (100+ stocks): active share of 20% or less against the closest benchmark, which is the S&P 500, S&P MidCap 400, S&P SmallCap 600, Russell 1000, Russell 2000, Nasdaq-100 or Dow Jones Industrial Average (weighted by an index-tracking fund's reported holdings or the index's constituents nearest the quarter end, over the names resolved to companies, and only when those are 90%+ of its weight) or every 13F filer's combined book, or index series holding 80%+ of the registered fund assets it advises (N-CEN) and equal to 50%+ of its book. Systematic-like: 500+ stocks, 100%+ annual turnover and a top 10 weight of 25% or less. Concentrated: a top 10 weight of 60%+ or 12 or fewer effective positions. Diversified active: none of these. Turnover is the smaller of buys and sells over average equity value, summed over four quarters: low under 30%, high 100%+. Horizon is the value-weighted number of quarters each position has been held: short under 4, long 12+.
Clone Performance
Build a hypothetical price-return history from this filer's public 13F holdings.
View clone backtestPortfolio Concentration
26 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Portfolio Trend
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $1,089,550,763 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| TSHA | Taysha Gene Therapies, Inc. | +833,333 | 9,693,244 | $66,010,991 | |
| DFTX | Definium Therapeutics, Inc. | +510,000 | 2,950,000 | $138,768,000 | |
| ABVX | Abivax S.A. | +316,000 | 993,000 | $132,327,180 | |
| PHVS | Pharvaris N.V. | +291,721 | 456,721 | $15,793,412 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| CNTX | Context Therapeutics Inc. | −2,200,000 | 3,050,000 | $1,689,700 | |
| TRVI | Trevi Therapeutics, Inc. | −1,170,000 | 315,000 | $5,874,750 | |
| OCUL | Ocular Therapeutix, Inc | −1,091,600 | 2,075,000 | $20,376,500 | |
| DTIL | Precision Biosciences Inc | −886,732 | 1,350,000 | $10,611,000 | |
| KYMR | Kymera Therapeutics, Inc. | −115,000 | 310,000 | $35,547,700 | |
| DNTH | Dianthus Therapeutics, Inc. | −105,000 | 1,841,667 | $179,525,699 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarterSold Out
Positions the filer fully exited| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| CNTA | Centessa Pharmaceuticals plc | 750,000 | $29,790,000 | |
| — | 1,450,000 | $29,188,500 | ||
| — | 530,000 | $27,941,600 | ||
| BBOT | BridgeBio Oncology Therapeutics, Inc. | 719,000 | $6,435,050 | |
| LXEO | Lexeo Therapeutics, Inc. | 1,100,000 | $6,314,000 | |
| CATX | Perspective Therapeutics, Inc. | 791,555 | $3,300,784 | |
| EVMN | Evommune, Inc. | 143,472 | $3,298,421 | |
| No positions match the current search. | ||||
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| DNTH |
Dianthus Therapeutics, Inc.
Healthcare
|
Reduced | 1,841,667 | $179,525,699 | 16.48% | |
| DFTX |
Definium Therapeutics, Inc.
Healthcare
|
Added | 2,950,000 | $138,768,000 | 12.74% | |
| ABVX |
Abivax S.A.
Healthcare
|
Added | 993,000 | $132,327,180 | 12.15% | |
| COGT |
Cogent Biosciences, Inc.
Healthcare
|
Held | 2,350,000 | $90,945,000 | 8.35% | |
| ALMS |
Alumis Inc.
Healthcare
|
Held | 2,830,700 | $79,655,898 | 7.31% | |
| AVBP |
ArriVent BioPharma, Inc.
Healthcare
|
Held | 1,971,054 | $68,474,415 | 6.28% | |
| TSHA |
Taysha Gene Therapies, Inc.
Healthcare
|
Added | 9,693,244 | $66,010,991 | 6.06% | |
| BIOA |
BioAge Labs, Inc.
Healthcare
|
Held | 1,748,000 | $42,843,480 | 3.93% | |
| MIRM |
Mirum Pharmaceuticals, Inc.
Healthcare
|
Held | 338,900 | $39,675,023 | 3.64% | |
| KYMR |
Kymera Therapeutics, Inc.
Healthcare
|
Reduced | 310,000 | $35,547,700 | 3.26% | |
| AKTS |
Aktis Oncology, Inc.
Healthcare
|
Held | 960,847 | $30,968,098 | 2.84% | |
| XENE |
Xenon Pharmaceuticals Inc.
Healthcare
|
Held | 490,000 | $29,576,400 | 2.71% | |
| PALI |
Palisade Bio, Inc.
Healthcare
|
Held | 10,276,317 | $21,477,502 | 1.97% | |
| OCUL |
Ocular Therapeutix, Inc
Healthcare
|
Reduced | 2,075,000 | $20,376,500 | 1.87% | |
| IRON |
Disc Medicine, Inc.
Healthcare
|
Held | 270,000 | $19,747,800 | 1.81% | |
| SMMT |
Summit Therapeutics Inc.
Healthcare
|
NEW | 1,250,000 | $18,212,500 | 1.67% | |
| PHVS |
Pharvaris N.V.
Healthcare
|
Added | 456,721 | $15,793,412 | 1.45% | |
| ANL |
Adlai Nortye Group Ltd.
Healthcare
|
NEW | 934,716 | $10,749,234 | 0.99% | |
| DTIL |
Precision Biosciences Inc
Healthcare
|
Reduced | 1,350,000 | $10,611,000 | 0.97% | |
| DBVT |
DBV Technologies S.A.
Healthcare
|
Held | 574,200 | $9,416,880 | 0.86% | |
| FTH |
Faeth Therapeutics, Inc.
Healthcare
|
NEW | 361,010 | $9,025,250 | 0.83% | |
| GYRE |
Gyre Therapeutics, Inc.
Healthcare
|
NEW | 954,416 | $6,289,601 | 0.58% | |
| TRVI |
Trevi Therapeutics, Inc.
Healthcare
|
Reduced | 315,000 | $5,874,750 | 0.54% | |
| UNCY |
Unicycive Therapeutics, Inc.
Healthcare
|
Held | 1,000,000 | $4,690,000 | 0.43% | |
| CNTX |
Context Therapeutics Inc.
Healthcare
|
Reduced | 3,050,000 | $1,689,700 | 0.16% | |
| GOSS |
Gossamer Bio, Inc.
Healthcare
|
Held | 7,750,000 | $1,278,750 | 0.12% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.